Drug Profile
Research programme: senolytic therapies - Ascentage Pharma/UNITY Biotechnology
Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Ascentage Pharma; UNITY Biotechnology
- Class Antiasthmatics; Antifibrotics; Neuroprotectants; Skin disorder therapies; Small molecules
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurodegenerative disorders
- No development reported Chronic obstructive pulmonary disease; Cognition disorders; Idiopathic pulmonary fibrosis; Kidney disorders; Systemic scleroderma
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in China
- 28 Sep 2022 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA
- 28 Sep 2022 No recent reports of development identified for preclinical development in Cognition-disorders in China